Comparative Functional Effects of Abemaciclib and Arcyriaflavin A in MYCN-Amplified and Non-Amplified Neuroblastoma Cells: An Exploratory Transcriptomic Study
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27167349 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Burcu Çerçi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Faculty of Medicine, Izmir Katip Celebi University, Cigli, Izmir 35620, Türkiye. Hauptthemen laut MEDLINE: Neuroblastoma, N-Myc Proto-Oncogene Protein, Transcriptome, Benzimidazoles. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Türkiye Sağlık Enstitüleri Başkanlığı, Health Institutes of Türkiye.
Abstract (Originalsprache)
Cyclin-dependent kinase (CDK) inhibitors are promising therapeutic agents for neuroblastoma, particularly in MYCN-amplified tumors; however, the molecular responses associated with CDK inhibition remain incompletely understood. MYCN-amplified BE(2)-C and MYCN-non-amplified SH-SY5Y neuroblastoma cells were treated with Abemaciclib or Arcyriaflavin A. Drug responses were evaluated using MTT, Annexin V ELISA, wound healing, colony formation, quantitative real-time PCR, and Western blot analyses. Exploratory transcriptomic profiling was performed by RNA sequencing. Because only one biological replicate was available per condition, transcriptomic analyses were limited to descriptive expression trends and pathway-oriented interpretation rather than statistical differential expression analysis. Both inhibitors reduced cell viability in a dose- and time-dependent manner, with BE(2)-C cells showing greater sensitivity than SH-SY5Y cells. Treatment also increased Annexin V levels, reduced wound closure, impaired clonogenic growth, and decreased CDK4/CDK6 expression, as confirmed by qRT-PCR and Western blotting. Exploratory transcriptomic profiling identified concordant expression trends in genes associated with cell-cycle regulation, DNA replication, and mitotic progression, with broader pathway modulation observed in MYCN-amplified cells. Overall, CDK inhibition suppresses proliferation-associated phenotypes in neuroblastoma and is accompanied by exploratory transcriptomic changes that identify candidate pathways for future validation and mechanistic investigation of MYCN-associated therapeutic responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biology, Faculty of Medicine, Izmir Katip Celebi University, Cigli, Izmir 35620, Türkiye.
- Vocational School of Health Services, Izmir Katip Celebi University, Cigli, Izmir 35620, Türkiye.
ORCID-Profile: Mustafa Soyöz
Förderung
- Türkiye Sağlık Enstitüleri Başkanlığı
- Health Institutes of Türkiye
Zitieren
APA
Çerçi, B., Karahan, H. İ., Soyöz, M., Pehlivan, M., & Pirim, İ. (2026). Comparative Functional Effects of Abemaciclib and Arcyriaflavin A in MYCN-Amplified and Non-Amplified Neuroblastoma Cells: An Exploratory Transcriptomic Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27167349
Vancouver
Çerçi B, Karahan Hİ, Soyöz M, Pehlivan M, Pirim İ. Comparative Functional Effects of Abemaciclib and Arcyriaflavin A in MYCN-Amplified and Non-Amplified Neuroblastoma Cells: An Exploratory Transcriptomic Study. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27167349
BibTeX
@article{eri2026,
author = {Çerçi, Burcu and Karahan, Hatice İlayhan and Soyöz, Mustafa and Pehlivan, Melek and Pirim, İbrahim},
title = {Comparative Functional Effects of Abemaciclib and Arcyriaflavin A in MYCN-Amplified and Non-Amplified Neuroblastoma Cells: An Exploratory Transcriptomic Study},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27167349}
}
EUVIMED